Introduction {#Sec1}
============

Breast cancer, the leading cause of cancer-related deaths worldwide, is a very heterogeneous disease. While the classical distinction between the two main forms of breast cancer, ductal and lobular, is still valid, DNA microarray analyses in the past decade have allowed the sub-classification of breast cancer based on gene expression patterns in normal-like, basal-like, human epidermal growth factor receptor 2/neu-overexpressing, luminal A, and luminal B cells \[[@CR1]\]. These subtypes have both prognostic and therapeutic relevance, although heterogeneity persists within each subtype. Independent from its sub-classification, metastatic spreading is mainly responsible for mortality of breast cancer patients, with overt metastases appearing in several cases 5--10 years after removal of the primary tumor. Extracellular vesicles (EVs), including ectosomes, also known as microvesicles (MVs), shed from the plasma membrane, and exosomes, derived from multivesicular bodies, are released from nearly all cells, but in increased quantities from cancer cells \[[@CR2]\], and have come to the limelight as biological entities involved in development and progression of breast cancer as well as most types of malignancies. Moreover, their possible exploitation as breast cancer biomarkers and potential components or targets of novel therapeutic strategies is increasingly evident.

Enveloped viruses spread infection through the replication of viral nucleic acids, assembly of viral elements, budding of mature viral particles, and subsequent fusion to surrounding cells \[[@CR3]\]. Both viruses and cancer-derived EVs contain proteins and nucleic acids that are transmitted to target cells in order to promote disease progression. Common morphological characteristics, protein content, and entry and release pathways between viruses and EVs produced from cancer cells, with a special emphasis on breast cancer, as well as the ability of viruses to utilize EV trafficking to spread pathogenesis are discussed in this review.

Physical Properties and Morphology {#Sec2}
==================================

A variety of techniques have been used to determine the morphology and size of EVs, including electron microscopy, nanoparticle tracking analysis (NTA), atomic force microscopy, and flow cytometry. Both exosomes and MVs are spherical in shape \[[@CR4]--[@CR6]\]. Although exosomes have traditionally been described as having a cup shape when viewed using transmission electron microscopy (TEM), this observation is an artifact of sample preparation and does not accurately reflect exosome morphology \[[@CR7]\]. Cancer-derived exosomes are typically smaller than MVs, with the former often ranging from 30 to 100 nm in size \[[@CR5], [@CR8]--[@CR10]\], and the latter having a larger size distribution, frequently being described between 100 nm to over 1 μm in diameter \[[@CR6], [@CR10], [@CR11]\]. Recently, an even smaller subset of EVs, 8--12 nm in diameter, called homogeneous nanovesicles from various cancerous cell lines and biological samples (human MDA-MB-231 breast carcinoma cells, 4T1 mouse mammary carcinoma cells, plasma from colon cancer patients and from mice implanted with 4T1 mammary tumor cells) has been reported \[[@CR12]\]. The size of EVs also can also vary depending upon the originating cell line as well as type of cancer. For example, exosomes from oral squamous cell carcinoma were 50--200 nm as measured by scanning electron microscopy \[[@CR13]\], while using the same NTA technique those derived from SKBR3 breast cancer were 183 ± 34 nm and those from murine B16F0 metastatic melanoma were 162 ± 23 nm \[[@CR7]\].

Due to the size similarities between them, there are problems obtaining purified viral particles because they are often contaminated with EVs and vice versa, so specific methodologies have to be employed when isolating virions or EVs to ensure a pure preparation devoid of unwanted materials \[[@CR14], [@CR15]\]. Like EVs, enveloped viruses can have a variety of sizes, ranging from 40 to 300 nm for those that are spherical in shape \[[@CR16]--[@CR18]\], although larger sizes have been reported as well \[[@CR19]\]. Similarly to EVs, enveloped viral particles can have different sizes depending upon the host cells from which they are released. For example, electron cryotomography showed the measles virus produced from Vero-SLAM cells to be 50--510 nm in size \[[@CR20]\], although measles are pleomorphic in shape, while measles virions produced from HeLa cells were determined to by 180--600 nm by TEM \[[@CR21]\].

Protein Content {#Sec3}
===============

It is well known that viruses incorporate host proteins within the viral core as well as in the envelope \[[@CR22]\]. However, there are also many proteins identified in EVs, including those derived from breast cancer, that are observed in enveloped virions as well \[[@CR23], [@CR24], [@CR25]••, [@CR26]\]. For example, proteins involved in endosomal trafficking pathways, such as syntaxin-12 and VAMP3, have also been identified within pseudorabies virus \[[@CR27]\], as well as in EVs derived from ovarian, colon, and non-small cell lung cancer \[[@CR28]--[@CR30]\]. The Epstein--Barr virus (EBV) and human cytomegalovirus (HCMV) have been found in breast cancer patients, although to date, no viruses have been conclusively proven to induce breast cancer \[[@CR31]\]. One interesting study examined the proteomics of SKBR3 breast cancer-derived EVs, using a 10,000×*g* centrifugation step to isolate larger plasma membrane-derived vesicles, 100,000×*g* centrifugation to isolate exosomes, followed by another 100,000×*g* centrifugation using a density gradient, or using size exclusion chromatography instead of centrifugations, prior to LC--MS/MS \[[@CR25]••\]. Table [1](#Tab1){ref-type="table"} lists proteins that are common to both breast cancer-derived EVs and enveloped EBV and HCMV viral particles. These virions and EVs contained a variety of shared protein classes, including cytoskeletal (i.e., moesin, β-actin, and filamin A), those involved in endocytosis (i.e., clathrin, PIK3C2A), autophagy (i.e., heat shock proteins, 14-3-3 proteins), and endocytic transport (i.e., annexins, RAB1A, CD81). There are also proteins in common between SKBR3 EVs and EBV/HCMV that are involved with protein folding (i.e., t-complex 1 (TCP1), chaperonin-containing TCP1 (CCT) proteins), cell adhesion/migration (i.e., galectin-1, α-enolase), and cell division \[i.e., cell division cycle 42 (CDC42), RAN binding protein 2 (RANBP2)\], indicating EVs and viral particles share more than transport and degradation routes, including proteins involved in significant cellular functions. Additionally, EBV, which has been shown to support the growth of nasopharyngeal cancer (NPC) \[[@CR32]\], expectedly shares many proteins with EVs derived from C666-1 (EBV-infected) NPC EVs (Table [1](#Tab1){ref-type="table"}) \[[@CR33]--[@CR35]\]. Interestingly, there seem to be more cellular proteins associated with EBV particles that have also been identified in breast cancer-derived EVs compared to those that have been identified in NPC EVs (Table [1](#Tab1){ref-type="table"}), further supporting a link between EBV and breast cancer. These studies suggest EBV and HCMV viral particles contain common cytoskeletal proteins, chaperones, and proteins involved in migration and cell division, as well as utilize similar intracellular trafficking routes as EVs, with particular similarities to breast cancer-derived EVs.Table 1Cellular proteins common to viruses and cancer-derived EVsProtein classProtein nameVirusCancerProtein classProtein nameVirusCancerEBV \[[@CR33]\]HCMV \[[@CR26]\]SKBR3 \[[@CR25]••\]\
(breast ADCA)C666-1 \[[@CR34], [@CR35]\]\
(NPC)EBV \[[@CR33]\]HCMV \[[@CR26]\]SKBR3 \[[@CR25]••\]\
(breast ADCA)C666-1 \[[@CR34], [@CR35]\]\
(NPC)Cytoskeletalβ-actin+++Endocytic vesicle sorting/traffickingCD81++γ-2-actin++Annexin A2++Actin-related protein 3++Annexin A6+++Alpha actinin 1++GAPDH+++Alpha actinin 4++RAB1A+++Plastin-2+++EHD1++Filamin A+++PRKAR2A++Moesin++Thioredoxin++Tubulin beta chain+++VCP+++Tubulin alpha 1A chain++MitosisRANBP2++Tubulin alpha 1C chain++CDC42++Cofilin-1+++eEF2+++Myosin-9++Signal transductionGNAI2++Profilin-1++SLC3A2+++S100A6++RISC complexSND1++Keratin Type I cytoskeletal 10++Protein foldingTCP1++Keratin Type II cytoskeletal 2 epidermal++CCT3+++Keratin Type II cytoskeletal 1++CCT5++Keratin Type I cytoskeletal 17++CCT7++Keratin Type II cytoskeletal 1b++CCT8++Keratin Type I cytoskeletal 19++Na+/K+ ATPaseATP1A1++Keratin Type I cytoskeletal 28++AutophagyHSPA5++Keratin Type II cytoskeletal 5++HSPA8++++Keratin Type II cytoskeletal 2 oral++HSP90AB4P++Keratin Type I cuticular Ha6++HSPA1A++eEF1A1++YWHAZ+++Cell adhesion/migrationGalectin-1++YWHAQ+++Alpha enolase++++YWHAE+++Lactadherin++Endocytosis/PhagocytosisClathrin heavy chain+++PPIA+++PIK3C2A++GlycolysisPyruvate kinase isozymes M1/M2++Lipid raftCD55++ALDOA+++*EBV* Epstein--Barr virus, *HCMV* human cytomegalovirus, *ADCA* adenocarcinoma, *NPC* nasopharyngeal carcinoma

Cellular Entry Pathways {#Sec4}
=======================

In addition to morphology and protein content, enveloped viruses and EVs also share cellular entry and release pathways. It is important to mention that EVs and enveloped viruses often utilize multiple pathways for cellular entry \[[@CR36]--[@CR40]\], perhaps to increase the efficiency of uptake. Figure [1](#Fig1){ref-type="fig"} outlines cellular entry pathways shared by cancer-derived EVs and enveloped viruses.Fig. 1Common routes of entry between EVs and enveloped viruses. Particles can enter target cells through mechanisms involving β-actin, such as macropinocytosis and phagocytosis. Additionally, particles can enter cells through clathrin-mediated, caveolin-mediated, or lipid raft-mediated endocytosis, prior to fusion with early endosomes. Additionally, vesicles/virions can migrate along filopodia to reach the base of the cell membrane prior to entrance. Low extracellular and endosomal pH influences particle uptake into vesicles, and early endosomes, respectively

pH {#Sec5}
--

Tumors are known to be acidic in nature, which results in a low pH surrounding the cancer cells and enhances cancer progression \[[@CR41]\]. Low extracellular pH also influences EV uptake, as shown by the significant increase in internalization of EVs from melanoma cells grown at low pH (6.0) as opposed to the physiological pH of 7.4 \[[@CR42]\]. However, an inhibition in internalization of EVs from metastatic breast cancer and prostate cancer cells was observed when grown at low pH (6.3) as opposed to the physiological pH of 7.4. It should be noted, however, that internalization of EVs was not affected by the pH of the medium where target cells were growing, but rather the surrounding pH of the cells which released the EVs \[[@CR43]\]. These conflicting results could indicate that extracellular pH variably affects EV entrance depending on cell type. Endosomal pH is also a determining factor for entry of enveloped viruses into host cells. When ammonium chloride, concanamycin, bafilomycin A1, or chloroquine, which make endosomes less acidic, were added to host cells, the infectivity of HIV-1 virions pseudotyped with hepatitis C virus (HCV) glycoproteins, HCV virions, or oropouche virions was reduced \[[@CR44]--[@CR46]\]. Additionally, decreases in extracellular pH can enhance vaccinia virus entry by promoting cellular membrane fusion and overcome the inhibition of viral entry caused by endosomal acidification inhibitors \[[@CR47]\]. Another study demonstrated that treatment of Huh 7.5 hepatocarcinoma cells with bafilomycin A1 or lansoprazole (another compound which raises endosomal pH) decreased the entry of, and subsequent infection from, EVs from HCV infected cells, as well as HCV virus \[[@CR48]\]. These studies suggest endocytosis of viral particles and EVs is affected by both extracellular and endosomal pH levels.

Clathrin- and Caveolin-Mediated Endocytosis {#Sec6}
-------------------------------------------

EVs isolated from the SKOV3 ovarian cancer cell line were shown to be taken up by target SKOV3 cells through clathrin-mediated (receptor-mediated) endocytosis \[[@CR37]\]. The inhibition of PC12 pheochromocytoma EV uptake was observed upon addition of inhibitors of clathrin-mediated endocytosis, such as potassium depletion buffer and chlorpromazine, as well as the knockdown of the CHC clathrin subunit or the subunit of the clathrin adaptor complex AP2 within target cells \[[@CR36]\]. Multiple enveloped viruses also enter hosts through clathrin-mediated endocytosis, such as rubella virus \[[@CR39]\] and HCV \[[@CR45]\]. Caveolin-1, an integral membrane protein often associated with lipid rafts, is also known to regulate endocytosis through lipid rafts \[[@CR49]\]. Both EVs, including pancreatic cancer-derived EVs \[[@CR38], [@CR50]\], and viruses such as coronavirus \[[@CR51]\], and Newcastle disease virus \[[@CR52]\] utilize caveolin-mediated endocytosis for cellular entry.

Lipids/Lipid Rafts {#Sec7}
------------------

Lipid rafts, which play an important role in cell signaling, are another mechanism for EVs and viruses to enter target cells. Glioblastoma EVs undergo lipid raft-dependent endocytosis, whose uptake is inhibited by caveolin-1, to enter HUVECs and glioblastoma cells \[[@CR53]\], and ovarian cancer EVs also utilize lipid rafts, independent of caveolin involvement, for their cellular uptake \[[@CR37]\]. Therefore, caveolin-1-dependent and lipid raft-dependent mechanisms are not necessarily synonymous. Additionally, breast cancer BT549-derived EVs enter cells through lipid rafts, which was indicated through the inhibition of EV internalization by treatment with methyl beta-cyclodextrin (MβCD), a disruptor of lipid rafts, as well as EV colocalization with cholera toxin B, which enters cells through lipid rafts \[[@CR54]\]. Herpes simplex virus (HSV) also employs lipid rafts for entry into a variety of host cells, including I143 epithelial cells, as well as SW480 and HT29 colon cancer cells, as shown by a decrease in viral infectivity upon addition of the cholesterol depletion compounds filipin and nystatin \[[@CR55]\]. Lipid raft involvement has also been observed in regard to the cellular entry of other viruses such as Japanese encephalitis virus and dengue virus (DENV) \[[@CR40], [@CR56]\]. Lipid content plays an important role in EV uptake, and the type of phospholipids present within EVs determine the extent of cellular entry \[[@CR43]\]. Sphingomyelin, phosphatidylserine (PS), and phosphatidylinositol are upregulated, while phosphatidylcholine is downregulated in EVs compared to their originating cell lines \[[@CR43]\]. Lipids such as PS on the EV/viral surface have also been reported to be involved in EV entry into squamous carcinoma cells \[[@CR57]\] and ovarian carcinoma cells \[[@CR58]\] as well as DENV \[[@CR59]\], and ebola virus \[[@CR60]\] entry into host cells.

Actin-Dependent Mechanisms {#Sec8}
--------------------------

Cytoskeletal components such as actin have a functional role in cellular uptake mechanisms, including phagocytosis, a process in which a cell engulfs foreign material into phagosomes, macropinocytosis, where large materials are taken up into vesicles called macropinosomes, in addition to endocytosis \[[@CR61]\]. Several studies have shown the actin polymerization inhibitor cytochalasin D was shown to decrease the uptake of EVs, including those derived from CEM T-cell lymphoblastic-like cells \[[@CR62]\], Jurkat T lymphocyte \[[@CR63]\], and K562 erythroleukemia cells \[[@CR64]\]. Similarly, treatment of host cells with cytochalasin B or D decreased the infectivity of rubella virus \[[@CR39]\] and amphotropic murine leukemia virus (A-MLV) \[[@CR65]\], respectively. More specifically, one group showed EV uptake occurred through phagocytosis by identifying K562 or MT4 (HTLV-transformed T-cell leukemia)-derived EVs colocalized with phagosomes in macrophages and showed their entry was dependent upon actin and dynamin-2, the latter protein being important for phagocytosis \[[@CR64]\]. HSV was determined to enter host cells through phagocytosis by a significant decrease in viral entry in host cells expressing a mutated form of dynamin-2 \[[@CR66]\]. Macropinocytosis as a mechanism for EV entry was determined through the decrease in uptake of PANC-1 pancreatic cancer-derived EVs upon addition of amiloride (a macropinocytosis inhibitor) \[[@CR38]\]. The inhibition of macropinocytosis and resulting decrease in PC12 pheochromocytoma-derived EV uptake was also achieved using a Na^+^--H^+^ exchange inhibitor (EIPA) and a phosphoinositide 3-kinase inhibitor (LY294002) \[[@CR36]\]. A separate study demonstrated that significantly more EVs produced from HeLa cervical adenocarcinoma cells entered A431 epidermoid carcinoma cells upon stimulation with epidermal growth factor, a protein known to induce macropinocytosis \[[@CR67]\]. Another study suggested that mRNA levels within EVs derived from 4T1 cells were quickly degraded within endocytic compartments after internalization and further observed EVs derived from HEK293FT cells colocalized with endocytic vesicles through the use of the macropinocytosis marker FITC-dextran \[[@CR68]\]. EIPA and/or amiloride were also used to determine that macropinocytosis was involved in the entry of A-MLV into host NIH 3T3 fibroblasts and HeLa cells \[[@CR65]\] and rubella virus into host Vero-E6 kidney cells \[[@CR39]\].

Filopodia Surfing {#Sec9}
-----------------

Recently, an interesting mechanism of EV entry has been shown to occur through "surfing" along cell extensions in order reach the cell membrane prior to endocytosis and colocalization with the endoplasmic reticulum \[[@CR69]•\]. EV uptake was reduced after addition of the actin polymerization inhibitor SMIFH2, which decreased the numbers of cellular filopodia, and indicated these protrusions were an essential component for EV uptake \[[@CR69]•\]. This type of transport into host cells can also be achieved by a variety of viruses \[[@CR70], [@CR71]\]. In particular, the murine leukemia virus (MLV) uses actin and myosin within the length of cellular filopodia to transport viral particles to the cell for subsequent infection \[[@CR72]\].

Cellular Release Pathways {#Sec10}
=========================

Endocytic Vesicles {#Sec11}
------------------

Interestingly, one common thread shared by EVs and viruses is the recruitment of the endosomal sorting complexes required for transport (ESCRTs) machinery to aid in cellular release \[[@CR73]\]. However, within the two major types of EVs---ectosomes and exosomes---the role of the ESCRT complexes differs. Exosome biogenesis utilizes all four types of ESCRTs, ESCRT-0, -I, -II, and -III. ESCRT-0 recognizes ubiquitinated proteins to be packaged into intraluminal vesicles (ILVs) within multivesicular bodies (MVBs) and recruits ESCRT-I \[[@CR73]\]. ESCRT-I and ESCRT-II also bind cargo and cluster at the endosomal membrane, prior to inward vesicular budding by ESCRT-III \[[@CR73]\]. One model suggests ESCRT-III, along with VPS4 ATPase, constricts the membrane to then facilitate fission \[[@CR74]\]. Upon maturation of the exosomal cargoes, MVBs proceed toward the outside of the cell and release their contents through fusion with the plasma membrane. This process is facilitated by a host of proteins belonging to the Rab GTPases family, notably RAB11, RAB35, and RAB27A/B \[[@CR75]\]. Bobrie et al. \[[@CR76]\] illustrated the importance of RAB27A in the secretion of exosomes from TS/A (non-metastatic) and 4T1 (metastatic) murine mammary carcinoma cells, as knockdown of this protein resulted in significantly decreased exosome numbers.

In contrast, the biogenesis of ectosomes is not well established. Generally, ectosomes are formed through the outward budding and fission of the plasma membrane. One particular study showed that the ESCRT-I subunit TSG101 may play a role in the direct release of ectosomes through plasma membrane budding \[[@CR77]\]. Upon recruitment to the plasma membrane, TSG101 bound to the arrestin 1 domain-containing protein 1 (ARRDC1) via a tetrapeptide motif, PSAP, and, along with VPS4 ATPase activity, resulted in ectosome release \[[@CR77]\].

The discovery of ARRDC1's function in vesicle formation and release gives light to the similarity of viral recruitment of the ESCRT machinery to mediate their release. Arrestin-related trafficking proteins such as ARRDC1 and thioredoxin interacting protein that bind to ESCRT machinery are also found to also be recruited by viruses \[[@CR78]\]. The Gag structures in viruses employ specific tetrapeptide motifs, including P(T/S)AP, YPXL, and PPXY, to recruit ESCRT and ESCRT-associated proteins. Similar to ectosome formation, Gag PTAP binds to TSG101, which along with VPS4, are required for viral release \[[@CR79]\]. Additionally, YPXL and PPXY bind to ALIX and NEDD4 proteins, respectively, which are important in viral release \[[@CR80], [@CR81]\]. The ability of viruses to mimic these interactions provides evidence of their efficiency in utilizing their host cells' endogenous vesicle-releasing machinery.

Actin-Dependent Mechanisms {#Sec12}
--------------------------

There are conflicting reports about the involvement of actin in EV release. One study reported that EV release from cervical cancer cells was dependent upon actin, as treatment of cells with cytochalasin D markedly reduced the amount of secreted EVs \[[@CR82]\]. However, another group demonstrated a significant increase in EV release upon treatment of HT29 colorectal cancer cells with cytochalasin D \[[@CR83]\]. Another study supported this increase in EV release from ovarian cancer cells after addition of cytochalasin D \[[@CR84]\], suggesting non-actin-dependent mechanisms of EV release. This discrepancy could have to do with the type of cell from which the EVs are released, with different cancer cell types utilizing separate release mechanisms. However, in MDA-MB-231 cells, as well as other cancer cell lines, the inhibition of ARF6, a regulator of ERK/MLCK actomyosin-based contraction, decreased EV release, further supporting an actin-based mechanism \[[@CR85]\] and confounding the overall necessity for actin in the release of cancer EVs. The role of actin in regard to virus release is more apparent, with actin depolymerization producing a decrease in enveloped vaccinia virus, measles virus, and respiratory syncytial virus (RSV) particle release \[[@CR86]--[@CR88]\].

Lipids/Lipid Rafts {#Sec13}
------------------

Ceramide is a sphingolipid that is located within lipid rafts and has a functional role in their organization and protein recruitment \[[@CR89]\]. Knockdown of neutral sphingomyelinase 2 (nSMase2), which produces ceramide, resulted in a decreased amount of EVs released from 4T1 mammary carcinoma cells \[[@CR90]\]. However, EV release from prostate PC-3 cells was not affected by inhibition of nSMase2 nor inhibition of ceramide synthase, although the knockdown of lipid raft proteins flotillin-1 and flotillin-2 altered the amounts of caveolin-1 and annexin A2 in exosomes \[[@CR91]\]. Therefore, the influence of lipid raft components on EV release varies from cell to cell. RSV \[[@CR92]\] and MLV release \[[@CR93]\] have also been reduced upon addition of MβCD, indicating viral release can also be dependent upon lipid rafts.

Viral Exploitation of EVs {#Sec14}
=========================

Due to the many similarities shared between EVs and enveloped viruses, it is not surprising that viruses have been postulated to exploit the exosome transport pathway as a means to incorporate host proteins and avoid immune detection, which has been coined the "Trojan exosome hypothesis" \[[@CR94]\]. Viruses also have the unique ability to transfer nucleic acids and proteins into host exosomes to promote infectivity. The utilization of the exosomal sorting and release pathway by viruses is especially evident in cancer cells, which secrete large amounts of EVs. One such example involves the HIV-1 Gag protein, which was localized to endosome-like regions and released into exosomes from infected Jurkat and K562 chronic myelogenous leukemia cells \[[@CR95]\]. Viruses can take advantage of these EVs and use them as a means to promote infectivity, as shown by viral transfer of sever fever with thrombocytopenia syndrome virus through EVs to infect host HeLa cells \[[@CR96]\]. In addition to proteins, viral nucleic acids can be transferred to host cells via EVs, which was demonstrated through the transfer of functional EBV miRNA to host monocyte-derived cells and resulting downregulation of miRNA targets \[[@CR97]\].

Viral-Regulated EV Content {#Sec15}
==========================

Cancer-associated viruses not only use the exosome transport pathway to promote viral infection, but to also spread oncogenes and proteins that will promote cancer progression. NPC-derived EVs have the ability to transfer the EBV latent membrane protein 1 (LMP1) as well as viral miRNAs to HUVEC cells and activate the AKT and ERK signaling pathways, which are known to promote cellular transformation and enhance tumor growth \[[@CR35]\]. A separate study also demonstrated that LMP1 upregulated hypoxia-inducible factor-1a (HIF-1α) in EVs derived from NPC cells \[[@CR98]\]. Additionally, they observed EV-associated HIF-1α was involved in the increase in levels of N-cadherin in HEK293T cells, which is a marker of the epithelial to mesenchymal transition \[[@CR98]\]. Therefore, enveloped viral particles associated with traditional pathogenesis as well as cancer transmission both utilize EVs within host cells to increase infectivity and enhance tumor growth, respectively. The miRNA content, including those that target oncogenes as well as tumor suppressors, of EVs has been shown to be altered by viral infection. For example, numerous EV miRNAs with multiple targets were identified to have altered expression profiles in patients with chronic hepatitis B, including miR-520b, miR-149, and miR-150 \[[@CR99]\]. While there is no direct correlation between EBV infection and EV miRNA content, there are a number of miRNAs that have been identified in viral-associated cancer (i.e., breast and prostate) EVs that have also shown to be modulated by EBV infection. A variety of miRNAs have been identified in metastatic and/or non-metastatic breast cancer EVs, including oncogenic miR-21, -23b, -27b, -181a, -378, as well as miR-26a, -151-3p, 151-5p, and let-7i \[[@CR100]•\]. These miRNAs have been found to have differential expression upon EBV infection of both B cells and diffuse large B cell lymphoma, with upregulation of the former miRNA group, and downregulation of the latter miRNA group \[[@CR101], [@CR102]\]. Additionally, EBV-infected host cells showed increased miR-146a and miR-34a levels, with the latter occurring through LMP1 expression and NF-κB activation \[[@CR101]\]. miR-34a and miR-146a were also identified as two prostate cancer EV biomarkers, with significantly decreased expression of miR-34a observed in prostate cancer tissue compared to healthy controls \[[@CR103]\]. Taken together, these studies suggest that EBV, a virus not only causally associated with NPC but also found in breast and prostate cancers, can regulate oncogenic or tumor-suppressive miRNA levels secreted into EVs, perhaps to enhance tumor growth in cancer patients.

Breast Cancer and Viral-Regulated EV Content {#Sec16}
============================================

Over the years numerous viruses including the mouse mammary tumor virus, HPV, the bovine papilloma virus, and EBV \[[@CR31]\] have been associated with human breast cancer, although the association has not risen to causal significance. Perhaps the reason for this is that some viruses may promote rather than initiate human breast cancer. The analogies mentioned in this review between mammalian EVs and enveloped viruses may explain the promotional role of both in the pathogenesis of human breast cancer. For example, HPV DNA sequences from the E6 gene region have been detected in human biopsy samples of invasive ductal carcinoma \[[@CR104]\]. The transduction of E6/E7 into MCF-7 and BT-20 breast cancer cells increased cell invasion and metastasis \[[@CR105]\]. A link between HPV and the content of cervical cancer EVs has been observed by Honegger et al. \[[@CR106]•\]. This group showed EV-associated miRNAs are regulated by the HPV oncogene E6/E7 within cervical cancer cells. For example, let-7d-5p, miR-378a-3p, and miR-92a-3p are significantly downregulated, and miR-21-5p, miR-100-5p, and miR-30c-5p are significantly upregulated in EVs by inhibition of E6/E7 in HeLa and/or SiHa cells, which led to the conclusion that E6/E7 expression influences EV miRNA content to enhance the levels of those with pro-tumorigenic properties \[[@CR106]•\]. These miRNAs that are influenced by E6/E7 are also expressed in EVs from breast cancer cells, as mentioned above for miR-21 and miR-378 \[[@CR100]•\]. EVs from MCF-7 cells have been found to contain and transfer miR-100 to target cells \[[@CR107]•\], and miR-92a, let-7d, and miR-30c have also been located in MCF-7 EVs \[[@CR108]\]. The combination of these studies raises the possibility that HPV within infected breast cancer cells can affect the miRNA content of breast cancer-derived EVs. Future studies could determine if HPV-regulated EV miRNAs or proteins have a direct promotional role in the progression of breast cancer.

Conclusions {#Sec17}
===========

Cancer-derived EVs, including both exosomes and MVs, are membrane-bound particles that share multiple characteristics with enveloped viruses, including morphology, protein content, and entry and release pathways. The entry of EVs and a variety of enveloped viruses into target cells is pH sensitive, dependent upon lipid rafts, and utilizes actin-dependent processes such as phagocytosis and macropinocytosis, among others. The release of both particle types includes similar mechanisms as those used for entry, including those involving actin as well as lipid rafts, but both viruses and EVs utilize ESCRT machinery for cellular release as well. In order to disseminate infection, enveloped viruses exploit the endosomal trafficking pathway, incorporating host proteins during intracellular transport. Viruses, including those associated with cancer, take advantage of the large quantities of EVs released from normal and transformed cells, using them to incorporate viral oncogenes and nucleic acids into target cells, which can enhance the spread of infection and cancer development. In the case of human breast cancer, although a causal viral association has not been demonstrated, the presence of EBV and HPV DNA in human breast cancer biopsies suggests a promotional role. Many cancer-associated miRNAs that are regulated by HPV are also present in breast cancer-derived EVs, suggesting the possibility of viral-linked EV content and breast cancer promotion. Furthermore, breast cancer-derived EVs have a particularly large number of proteins, including those found in the endocytic pathway, which have also been identified in viral particles, supporting mutual cellular transport routes. The multitude of these similarities suggests EVs, including those derived from breast cancer, and viruses may have evolved from a common origin, with both serving as tools for the pathogenesis of disease.
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